The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Objective: Inflammation has emerged as an important factor in disease progression in human and transgenic models of amyotrophic lateral sclerosis (ALS). Recent studies demonstrate that the prostaglandin E 2 EP2 receptor is a major regulator of inflammatory oxidative injury in innate immunity. We tested whether EP2 signaling participated in disease pathogenesis in the G93A superoxide dismutase (SOD) model of familial ALS. Methods: We examined the phenotype of G93A SOD mice lacking the EP2 receptor and performed immunocytochemistry, quantitative reverse transcriptase polymerase chain reaction, and Western analyses to determine the mechanism of EP2 toxicity in this model. Results: EP2 receptor is significantly induced in G93A SOD mice in astrocytes and microglia in parallel with increases in expression of proinflammatory enzymes and lipid peroxidation. In human ALS, EP2 receptor immunoreactivity was upregulated in astrocytes in ventral spinal cord. In aging G93A SOD mice, genetic deletion of the prostaglandin E 2 EP2 receptor improved motor strength and extended survival. Deletion of the EP2 receptor in G93A SOD mice resulted in significant reductions in levels of proinflammatory effectors, including cyclooxygenase‐1, cyclooxygenase‐2, inducible nitric oxide synthase, and components of the NADPH oxidase complex. In alternate models of inflammation, including the lipopolysaccharide model of innate immunity and the APPSwe‐PS1ΔE9 model of amyloidosis, deletion of EP2 also reduced expression of proinflammatory genes. Interpretation: These data suggest that prostaglandin E 2 signaling via the EP2 receptor functions in the mutant SOD model and more broadly in inflammatory neurodegeneration to regulate expression of a cassette of proinflammatory genes. Inhibition of EP2 signaling may represent a novel strategy to downregulate the inflammatory response in neurodegenerative disease. Ann Neurol 2008;64:304–314
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Onset and Progression in Inherited ALS Determined by Motor Neurons and Microglia
Boillée, S., Yamanaka, K., Lobsiger, C. S., Copeland, N. G., Jenkins, N. A., Kassiotis, G., Kollias, G., & Cleveland, D. W. (2006) · Science · doi:10.1126/science.1123511 · Cited by 1,623
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196
Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis
Yamanaka, K., Chun, S. J., Boillee, S., Fujimori-Tonou, N., Yamashita, H., Gutmann, D. H., Takahashi, R., Misawa, H., & Cleveland, D. W. (2008) · Nature Neuroscience · doi:10.1038/nn2047 · Cited by 1,140
Risk of Alzheimer's disease and duration of NSAID use
Stewart, W. F., Kawas, C., Corrada, M., & Metter, E. J. (1997) · Neurology · doi:10.1212/wnl.48.3.626 · Cited by 1,132
Prostanoid Receptors: Subtypes and Signaling
Breyer, R. M., Bagdassarian, C. K., Myers, S. A., & Breyer, M. D. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.661 · Cited by 1,011 · cited 1×
“E-prostanoid receptor), FP, DP, IP, and TP receptors.(16) Recent studies demonstrate that the PGE2 EP2 receptor promotes inflammatory injury in models of innate immunity and Alzheimer’s disease.”
BackgroundSelf-citationPGH synthase and lipoxygenase generate superoxide in the presence of NADH or NADPH.
Kukreja, R. C., Kontos, H. A., Hess, M. L., & Ellis, E. F. (1986) · Circulation Research · doi:10.1161/01.res.59.6.612 · Cited by 487 · cited 1×
“A third source of ROS is COX-1 and COX-2 that produce superoxide in the conversion of arachidonic acid to PGH2 as a by-product of the peroxidase activity of the enzyme.(22) We examined the regulation of expression of selected NADPH oxidase subunits, COX-1, the inducible COX-2, and iNOS in 1- and 3.”
BackgroundInflammatory processes in amyotrophic lateral sclerosis
McGeer, P. L., & McGeer, E. G. (2002) · Muscle & Nerve · doi:10.1002/mus.10191 · Cited by 470
Screening of innate immune receptors in neurodegenerative diseases: A similar pattern
Letiembre, M., Liu, Y., Walter, S., Hao, W., Pfander, T., Wrede, A., Schulz-Schaeffer, W., & Fassbender, K. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.08.018 · Cited by 228
Lüth, H.-J., Holzer, M., Gärtner, U., Staufenbiel, M., & Arendt, T. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02758-5 · Cited by 183 · cited 1×
“The induction of eNOS may reflect induction of this isoform in endothelial and astrocytic cells.(29) The effect of EP2 deletion on the NOS isoforms was specific to iNOS and eNOS, and did not impact on the FasL-nNOS pathway(26) in which NO-mediated increases in FasL-Fas signaling upregulate nNOS expression in motor neu…”
BackgroundRedox modifier genes in amyotrophic lateral sclerosis in mice
Marden, J. J., Harraz, M. M., Williams, A. J., Nelson, K., Luo, M., Paulson, H., & Engelhardt, J. F. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31265 · Cited by 145
Microglial EP2 is critical to neurotoxicity from activated cerebral innate immunity
Shie, F., Montine, K. S., Breyer, R. M., & Montine, T. J. (2005) · Glia · doi:10.1002/glia.20220 · Cited by 110
Self-citation
Cited by
NOX Enzymes in the Central Nervous System: From Signaling to Disease
Sorce, S., & Krause, K.-H. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2578 · Cited by 471
Neuronal Lipid Metabolism: Multiple Pathways Driving Functional Outcomes in Health and Disease
Tracey, T. J., Steyn, F. J., Wolvetang, E. J., & Ngo, S. T. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00010 · Cited by 433
Ludin, A., Gur-Cohen, S., Golan, K., Kaufmann, K. B., Itkin, T., Medaglia, C., Lu, X.-J., Ledergor, G., Kollet, O., & Lapidot, T. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2014.5941 · Cited by 335
Targeting innate immunity for neurodegenerative disorders of the central nervous system
Andreasson, K. I., Bachstetter, A. D., Colonna, M., Ginhoux, F., Holmes, C., Lamb, B., Landreth, G., Lee, D. C., Low, D., Lynch, M. A., et al. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13667 · Cited by 126
Self-citationJohansson, J. U., Pradhan, S., Lokteva, L. A., Woodling, N. S., Ko, N., Brown, H. D., Wang, Q., Loh, C., Cekanaviciute, E., Buckwalter, M., et al. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.2203-13.2013 · Cited by 96
“In transgenic models of Alzheimer's disease and amyotrophic lateral sclerosis, where neurodegeneration occurs in the setting of a prominent innate immune response, global deletion of EP2 attenuates progression of pathology (Liang et al., 2005, 2008; Keene et al., 2010).”
BackgroundMethodSelf-citation
Metadata
- Authors
- Liang, X., Wang, Q., Shi, J., Lokteva, L., Breyer, R. M., Montine, T. J., & Andreasson, K.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2008-09-28
- Volume
- 64
- Issue
- 3
- Pages
- 304-314
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W1968358948
- Cited by
- 119
- References
- 11
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.